Current Report Filing (8-k)
13 Mars 2023 - 11:03AM
Edgar (US Regulatory)
0001293310
false
0001293310
2023-03-10
2023-03-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________
FORM 8-K
_____________________________
CURRENT REPORT
Pursuant to Section 13 or
15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 10, 2023
_____________________________
Humanigen, Inc.
(Exact name of registrant as specified in its charter) |
|
Delaware
(State or other Jurisdiction of
Incorporation) |
001-35798
(Commission File No.) |
77-0557236
(IRS Employer Identification No.) |
|
830 Morris Turnpike, 4th Floor
Short Hills, New Jersey 07078
(Address of principal executive offices and zip code) |
|
(973) 200-3010
(Registrant's telephone number, including area code) |
|
N/A
(Former name or former address, if changed since
last report) |
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
|
|
o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
|
|
Securities registered pursuant to Section 12(b) of the Act: |
|
|
|
Title of each class |
Trading
Symbol(s) |
Name of each exchange on which registered |
|
Common Stock |
HGEN |
The Nasdaq Stock Market LLC |
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
|
Emerging growth company |
o |
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |
o |
|
|
|
|
|
|
|
Item 7.01 Regulation FD Disclosure.
Humanigen, Inc. confirms that it does not
hold any deposits or securities or maintain any accounts at Silicon Valley Bank.
The information in this Item 7.01 is being
furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of that Section. The information in this Item 7.01 shall not be incorporated by reference into
any registration statement or other document pursuant to the Securities Act of 1933, as amended.
SIGNATURE
Pursuant to the requirements of the Securities and
Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
HUMANIGEN, INC. |
|
|
Dated: March 13, 2023 |
By: /s/ Cameron Durrant |
|
Name: |
Cameron Durrant |
|
Title: |
Chairman of the Board and Chief Executive Officer |
Humanigen (NASDAQ:HGEN)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Humanigen (NASDAQ:HGEN)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
Real-Time news about Humanigen Inc (NASDAQ): 0 recent articles
Plus d'articles sur Humanigen, Inc